Pasireotide LAR Improves Biochemical Control: Crossover Extension to a Randomized, Double-Blind, Multicenter, Phase III Study P Freda,1 M Fleseriu,2 AJ van der Lely,3 A Colao,4 A Sheppard M,5 F Gu,6 C-C Shen,7 M Gadelha,8 AJ Farrall,9 K Hermosillo Resendiz,10 M Ruffin,11 Y Chen,10 and MD Bronstein12 1Department of Medicine, Columbia University College of Physicians & Surgeons, New York, New York, USA; 2Department of Medicine and Neurological Surgery, Northwest Pituitary Center, Oregon Health & Science University, Portland, Oregon, USA; 3Department of Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands; 4Dipartimento di Medicina Clinica e Chirurgia, Universita Federico II di Napoli, Naples, Italy; 5Centre for Endocrinology, Diabetes and Metabolism, University of Birmingham, Edgbaston, Birmingham, UK; 6Department of Endocrinology, Key Laboratory of Endocrinology, Ministry of Health, Peking Union Medical College Hospital, Beijing, China; 7Department of Neurosurgery, Tri-Service General Hospital and National Defense Medical Center, Taipei, Taiwan, ROC and the Department of Physical Therapy, Hungkuang University, Taichung, Taiwan; 8Endocrine Unit, Hospital Universitario Clementino Fraga Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil; 9Brain Research Imaging Centre, University of Edinburgh, Edinburgh, UK; 10Clinical Development, Novartis Pharmaceuticals Corporation, Florham Park, New Jersey, USA; 11Clinical Development, Oncology Business Unit, Novartis Pharma AG, Basel, Switzerland; 12Neuroendocrine Unit, Division of Endocrinology and Metabolism, University of Sao Paulo Medical School, Sao Paulo, Brazil